SOL Bio develops in vitro diagnostic products utilizing exosome-based liquid biopsy tests to detect early-stage cancer through efficient cancer cell isolation. Their technology addresses the need for low-cost, accurate cancer screening by leveraging exosomes as biomarkers for molecular communication between cells.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Early cancer detection methods often involve invasive procedures or lack the sensitivity to identify cancer in its initial stages. Traditional diagnostic approaches can also be expensive and time-consuming, limiting accessibility for widespread screening.
Solution
SOL Bio develops in vitro diagnostic products that utilize exosome-based liquid biopsy tests for early cancer detection. Their technology focuses on isolating and analyzing exosomes, nano-sized vesicles secreted by cells, including cancer cells, which contain molecular information. By leveraging exosomes as biomarkers, SOL Bio aims to provide a less invasive and more accessible method for detecting cancer at an early stage, potentially improving treatment outcomes. The company combines biosensor manufacturing experience with AI to develop low-cost cancer screening solutions.
Target Audience
The primary target audience includes healthcare providers, diagnostic laboratories, and research institutions focused on early cancer detection and personalized medicine.
Features
- Exosome isolation protocol for liquid biopsy tests
- Utilizes exosomes as biomarkers for early cancer detection
- Development of in vitro diagnostic products
- Focus on non-invasive cancer screening methods
- Integration of AI for improved diagnostic accuracy